Effettuare il login Iscriviti gratis

Last updated: 3 July 2024 at 5:03pm EST

Michael Mulroy Net Worth




The estimated Net Worth of Michael H. Mulroy is at least $224 Mille dollars as of 24 March 2022. Mr. Mulroy owns over 7,000 units of Lineage Cell Therapeutics Inc stock worth over $223,702 and over the last 9 years he sold LCTX stock worth over $0. In addition, he makes $0 as Independent Director at Lineage Cell Therapeutics Inc.

Mr. Mulroy LCTX stock SEC Form 4 insiders trading

Michael has made over 14 trades of the Lineage Cell Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 7,000 units of LCTX stock worth $9,800 on 24 March 2022.

The largest trade he's ever made was exercising 24,720 units of Lineage Cell Therapeutics Inc stock on 18 June 2021 worth over $54,384. On average, Michael trades about 2,094 units every 55 days since 2015. As of 24 March 2022 he still owns at least 258,555 units of Lineage Cell Therapeutics Inc stock.

You can see the complete history of Mr. Mulroy stock trades at the bottom of the page.





Michael Mulroy biography

Michael H. Mulroy serves as Independent Director of the Company. Mr. Mulroy served as the Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc. (AST) from June 2017 until our acquisition of Asterias in March 2019. In April 2020, Mr. Mulroy joined Magtrol Inc., a leading manufacturer of motor test equipment and hysteresis brakes and clutches, on a part time basis, where he also serves on its board of directors. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC (now part of PJT Partners Inc.), which assists companies in connection with investor engagement and complex corporate governance issues. Prior to its sale in 2014, Mr. Mulroy served as Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor Pharmaceuticals, Inc. (QCOR). Mr. Mulroy joined Questcor in 2011 as Chief Financial Officer, General Counsel and Corporate Secretary. From 2003 to 2011, Mr. Mulroy was employed by the law firm of Stradling Yocca Carlson & Rauth, where he served as a partner from 2004. From 1997 to 2003, Mr. Mulroy was an investment banker at Citigroup and Merrill Lynch. He is also a member of the Board of Trustees of the Pegasus School, an independent primary school in Orange County, California. From January 2017 to July 2019, Mr. Mulroy served as a member of the board of directors of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. From July 2011 to August 2014, Mr. Mulroy served as a member of the board of directors of Comarco, Inc. (CMRO), a defense services company transformed into a wireless communication products company. Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. degree in economics from the University of Chicago. Mr. Mulroy brings to our Board his experience as the Chief Executive Officer of a publicly traded biotechnology company and member of a seni



How old is Michael Mulroy?

Michael Mulroy is 54, he's been the Independent Director of Lineage Cell Therapeutics Inc since 2014. There are 7 older and 8 younger executives at Lineage Cell Therapeutics Inc. The oldest executive at Lineage Cell Therapeutics Inc is Alfred Kingsley, 77, who is the Chairman of the Board.

What's Michael Mulroy's mailing address?

Michael's mailing address filed with the SEC is C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008.

Insiders trading at Lineage Cell Therapeutics Inc

Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley e Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.



What does Lineage Cell Therapeutics Inc do?

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.



What does Lineage Cell Therapeutics Inc's logo look like?

Lineage Cell Therapeutics Inc logo

Complete history of Mr. Mulroy stock trades at AgeX Therapeutics Inc e Lineage Cell Therapeutics Inc

Data
#
Ditta
 Persona
Trans.
Transazione
 Azioni Prezzo per azione Prezzo totale Azioni dopo Fonte
24 Mar 2022 LCTX Lineage Cell Therapeutics Inc Michael H. Mulroy
Acquistare 7,000 $1.40 $9,800
24 Mar 2022
258,555 ↗
18 Jun 2021 LCTX Lineage Cell Therapeutics Inc Michael H. Mulroy
Opzione 24,720 $2.20 $54,384
18 Jun 2021
251,555 ↗


Lineage Cell Therapeutics Inc executives and stock owners

Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include: